1.71
+0.155(+9.97%)
Currency In USD
| Previous Close | 1.56 |
| Open | 1.56 |
| Day High | 1.73 |
| Day Low | 1.52 |
| 52-Week High | 3.26 |
| 52-Week Low | 1.12 |
| Volume | 73,054 |
| Average Volume | 18,176 |
| Market Cap | 17.4M |
| PE | -1.1 |
| EPS | -1.56 |
| Moving Average 50 Days | 1.46 |
| Moving Average 200 Days | 1.81 |
| Change | 0.16 |
If you invested $1000 in Cocrystal Pharma, Inc. (COCP) 10 years ago, it would be worth $3.86 as of June 01, 2025 at a share price of $1.71. Whereas If you bought $1000 worth of Cocrystal Pharma, Inc. (COCP) shares 5 years ago, it would be worth $150 as of June 01, 2025 at a share price of $1.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein
Cocrystal Pharma to Participate in Noble Capital Markets’ 2025 Emerging Growth Virtual Equity Conference
GlobeNewswire Inc.
May 28, 2025 12:00 PM GMT
BOTHELL, Wash., May 28, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that management will participate in a fireside chat during the Noble Capital Markets’ 2025 Emerging Growth Virtual Equit
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
GlobeNewswire Inc.
Apr 24, 2025 12:00 PM GMT
Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-sp